FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Report of Foreign Private Issuer
Pursuant to Rule 13s - 16 or 15d - 16 of
the Securities Exchange Act of 1934
For the month of November, 2006
Acambis plc
(Translation of registrant's name into English)
Peterhouse Technology Park
100 Fulbourn Road
Cambridge CB1 9PT
England
(address of principal executive offices)
(Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F
Forms 20-F X Form 40-F
Indicate by check mark whether the registrant by furnishing the information
contained in this Form also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934).
Yes No X
(if "Yes" is marked, indicate below the file number assigned to the registrant
in connection with Rule 12g3-2(b): 82- ).
Enclosure:
1. Holding(s) in Company
2. Holding(s) in Company
3. Holding(s) in Company
4. Holding(s) in Company
5. Holding(s) in Company
Enclosure No. 1
Holding in Company
Cambridge, UK and Cambridge, Massachusetts - 3 November 2006 - Acambis plc
("Acambis") (LSE: ACM, NASDAQ: ACAM) announces an interest in its shares by The
Goldman Sachs Group, Inc.
On 2 November 2006, Acambis received notification that, as of the close of
business on 31 October 2006, The Goldman Sachs Group, Inc., ("GS Inc") of 85
Broad Street, New York, NY 10004, USA, was interested in a total of 10,898,113
ordinary shares of 10p each, representing a 10.15% holding of Acambis' issued
share capital.
Of these 10,898,113 shares:
a) the interest in 462,965 shares arose from an interest held by Goldman,
Sachs & Co. ("GS&Co."), a direct subsidiary of GS Inc., acting as
custodian; these shares are, or will be, registered in the name of Goldman
Sachs Securities (Nominees), Limited ("GSSN");
b) the interest in 3,300 shares arose from an interest held by GS&Co, a direct
subsidiary of GS Inc, acting as a discretionary manager. These shares are,
or will be, registered in the name of GSSN;
c) the interest in 344,700 shares arose from an interest held by GS&Co, acting
as custodian of 172,350 American Depositary Receipts ("ADRs"); these ADRs
are, or will be, held at The Depositary Trust Company, New York;
d) the interest in 10,087,148 shares arose from a beneficial interest held by
Goldman Sachs International, a direct subsidiary of GS Inc; these shares
are, or will be, registered at CREST in account CREPTEMP.
-ends-
Enquiries:
Acambis plc
Elizabeth Brown, Company Secretary: Tel: +44 (0) 1223 275 300
Lyndsay Wright, VP, Communications and Investor
Relations: Tel: +44 (0) 1223 275 300
About Acambis
Acambis is a leading biotechnology company targeting infectious diseases with
novel vaccines. Acambis' development-stage pipeline includes vaccines that could
either offer improvements over existing products or target unmet medical needs.
Its investigational vaccine against Japanese encephalitis, ChimeriVax-JE, which
is undergoing Phase 3 clinical testing, is intended to provide an "ideal"
vaccine to address the estimated 50,000 cases of this viral disease in Asia
every year. Acambis' proprietary ChimeriVax technology, developed in association
with St Louis University, has also been used to develop ChimeriVax-West Nile,
which is undergoing Phase 2 clinical testing, making it the most advanced
investigational vaccine against the West Nile virus. Acambis also has the only
vaccine in development against Clostridium difficile bacteria, a leading cause
of hospital-acquired infections. Recognised internationally as the leading
producer of smallpox vaccines, Acambis is developing an investigational smallpox
vaccine, ACAM2000, and is manufacturing emergency-use stockpiles of this
investigational vaccine for the US Government and other governments around the
world. It is also developing an attenuated smallpox vaccine, MVA3000, under
contracts with the US National Institutes of Health.
Acambis is based in Cambridge, UK and Cambridge, Massachusetts, US, and is
listed on the London Stock Exchange (ACM). Its shares are listed on NASDAQ
(ACAM) in the form of American Depositary Receipts. More information is
available at www.acambis.com.
"Safe Harbor" statement under the Private Securities Litigation Reform Act of
1995:
The statements in this news release that are not historical facts are
forward-looking statements that involve risks and uncertainties, including the
timing and results of clinical trials, product development, manufacturing and
commercialisation risks, the risks of satisfying the regulatory approval process
in a timely manner, the need for and the availability of additional capital. For
a discussion of these and other risks and uncertainties see "Risk management" in
the Company's 2005 Annual Report and "Risk factors" in its Form 20-F, in
addition to those detailed on the Company's website and in the Company's filings
made with the Securities and Exchange Commission from time to time. These
forward-looking statements are based on estimates and assumptions made by the
management of Acambis and are believed to be reasonable, though are inherently
uncertain and difficult to predict. Actual results or experience could differ
materially from the forward-looking statements.
Enclosure No. 2
SCHEDULE 10
NOTIFICATION OF MAJOR INTERESTS IN SHARES
1. Name of company
Acambis plc
2. Name of shareholder having a major interest
Barclays PLC
3. Please state whether notification indicates that it is in respect of holding
of the shareholder named in 2 above or in respect of a non-beneficial interest
or in the case of an individual holder if it is a holding of that person's
spouse or children under the age of 18
As above
4. Name of the registered holder(s) and, if more than one holder, the number of
shares held by each of them
The legal entities holding these shares are as follows:
Barclays Capital Securities Ltd 1,873,194 shares
Barclays Capital Inc 2,616 shares
Gerrard Ltd 5,275 shares
Barclays Global Investors Ltd 1,316,547 shares
Barclays Life Assurance Co Ltd 135,352 shares
5. Number of shares / amount of stock acquired
Not disclosed
6. Percentage of issued class
Not disclosed
7. Number of shares / amount of stock disposed
N/A
8. Percentage of issued class
N/A
9. Class of security
Ordinary shares of 10p each
10. Date of transaction
Not disclosed
11. Date company informed
8 November 2006
12. Total holding following this notification
3,332,984 shares
13. Total percentage holding of issued class following this notification
3.10%
14. Any additional information
N/A
15. Name of contact and telephone number for queries
Elizabeth Brown tel: 01223 275300
16. Name and signature of authorised company official responsible for making
this notification
Elizabeth Brown, Company Secretary
Date of notification
9 November 2006
The FSA does not give any express or implied warranty as to the accuracy of this
document or material and does not accept any liability for error or omission.
The FSA is not liable for any damages (including, without limitation, damages
for loss of business or loss of profits) arising in contract, tort or otherwise
from the use of or inability to use this document, or any material contained in
it, or from any action or decision taken as a result of using this document or
any such material.
Enclosure No. 3
Holding in Company
Cambridge, UK and Cambridge, Massachusetts - 17 November 2006 - Acambis plc
("Acambis") (LSE: ACM, NASDAQ: ACAM) announces an interest in its shares by The
Goldman Sachs Group, Inc.
On 16 November 2006, Acambis received notification that, as of the close of
business on 14 November 2006, The Goldman Sachs Group, Inc., ("GS Inc") of 85
Broad Street, New York, NY 10004, USA, was interested in a total of 12,447,408
ordinary shares of 10p each, representing an 11.59% holding of Acambis' issued
share capital.
Of these 12,447,408 shares:
a) the interest in 462,965 shares arose from an interest held
by Goldman, Sachs & Co. ("GS&Co."), a direct subsidiary of GS Inc., acting as
custodian; these shares are, or will be, registered in the name of Goldman Sachs
Securities (Nominees), Limited ("GSSN");
b) the interest in 3,300 shares arose from an interest held by
GS&Co, a direct subsidiary of GS Inc, acting as a discretionary manager. These
shares are, or will be, registered in the name of GSSN;
c) the interest in 344,700 shares arose from an interest held
by GS&Co, acting as custodian of 172,350 American Depositary Receipts ("ADRs");
these ADRs are, or will be, held at The Depositary Trust Company, New York;
d) the interest in 11,636,443 shares arose from a beneficial
interest held by Goldman Sachs International, a direct subsidiary of GS Inc;
these shares are, or will be, registered at CREST in account CREPTEMP.
-ends-
Enquiries:
Acambis plc
Elizabeth Brown, Company Secretary: Tel: +44 (0) 1223 275 300
Lyndsay Wright, VP, Communications and Investor Relations:
Tel: +44 (0) 1223 275 300
About Acambis
Acambis is a leading biotechnology company targeting infectious diseases with
novel vaccines. Acambis' development-stage pipeline includes vaccines that could
either offer improvements over existing products or target unmet medical needs.
Its investigational vaccine against Japanese encephalitis, ChimeriVax-JE, which
is undergoing Phase 3 clinical testing, is intended to provide an "ideal"
vaccine to address the estimated 50,000 cases of this viral disease in Asia
every year. Acambis' proprietary ChimeriVax technology, developed in association
with St Louis University, has also been used to develop ChimeriVax-West Nile,
which is undergoing Phase 2 clinical testing, making it the most advanced
investigational vaccine against the West Nile virus. Acambis also has the only
vaccine in development against Clostridium difficile bacteria, a leading cause
of hospital-acquired infections. Recognised internationally as the leading
producer of smallpox vaccines, Acambis is developing an investigational smallpox
vaccine, ACAM2000, and is manufacturing emergency-use stockpiles of this
investigational vaccine for the US Government and other governments around the
world. It is also developing an attenuated smallpox vaccine, MVA3000, under
contracts with the US National Institutes of Health.
Acambis is based in Cambridge, UK and Cambridge, Massachusetts, US, and is
listed on the London Stock Exchange (ACM). Its shares are listed on NASDAQ
(ACAM) in the form of American Depositary Receipts. More information is
available at www.acambis.com.
"Safe Harbor" statement under the Private Securities Litigation Reform Act of
1995:
The statements in this news release that are not historical facts are
forward-looking statements that involve risks and uncertainties, including the
timing and results of clinical trials, product development, manufacturing and
commercialisation risks, the risks of satisfying the regulatory approval process
in a timely manner, the need for and the availability of additional capital. For
a discussion of these and other risks and uncertainties see "Risk management" in
the Company's 2005 Annual Report and "Risk factors" in its Form 20-F, in
addition to those detailed on the Company's website and in the Company's filings
made with the Securities and Exchange Commission from time to time. These
forward-looking statements are based on estimates and assumptions made by the
management of Acambis and are believed to be reasonable, though are inherently
uncertain and difficult to predict. Actual results or experience could differ
materially from the forward-looking statements.
Enclosure No. 4
Holding in Company
Cambridge, UK and Cambridge, Massachusetts - 21 November 2006 - Acambis plc
("Acambis") (LSE: ACM, NASDAQ: ACAM) announces an interest in its shares by The
Goldman Sachs Group, Inc.
On 20 November 2006, Acambis received notification that, as of the close of
business on 16 November 2006, The Goldman Sachs Group, Inc., ("GS Inc") of 85
Broad Street, New York, NY 10004, USA, was interested in a total of 13,076,549
ordinary shares of 10p each, representing a 12.18% holding of Acambis' issued
share capital.
Of these 13,076,549 shares:
a) the interest in 462,965 shares arose from an interest held by Goldman, Sachs
& Co. ("GS&Co."), a direct subsidiary of GS Inc., acting as custodian; these
shares are, or will be, registered in the name of Goldman Sachs Securities
(Nominees), Limited ("GSSN");
b) the interest in 3,300 shares arose from an interest held by GS&Co, a direct
subsidiary of GS Inc, acting as a discretionary manager. These shares are,
or will be, registered in the name of GSSN;
c) the interest in 351,300 shares arose from an interest held by GS&Co, acting
as custodian of 176,650 American Depositary Receipts ("ADRs"); these ADRs
are, or will be, held at The Depositary Trust Company, New York;
d) the interest in 12,258,984 shares arose from a beneficial interest held by
Goldman Sachs International, a direct subsidiary of GS Inc; these shares
are, or will be, registered at CREST in account CREPTEMP.
-ends-
Enquiries:
Acambis plc
Elizabeth Brown, Company Secretary:
Tel: +44 (0) 1223 275 300
Lyndsay Wright, VP, Communications and Investor Relations:
Tel: +44 (0) 1223 275 300
About Acambis
Acambis is a leading biotechnology company targeting infectious diseases with
novel vaccines. Acambis' development-stage pipeline includes vaccines that could
either offer improvements over existing products or target unmet medical needs.
Its investigational vaccine against Japanese encephalitis, ChimeriVax-JE, which
is undergoing Phase 3 clinical testing, is intended to provide an "ideal"
vaccine to address the estimated 50,000 cases of this viral disease in Asia
every year. Acambis' proprietary ChimeriVax technology, developed in association
with St Louis University, has also been used to develop ChimeriVax-West Nile,
which is undergoing Phase 2 clinical testing, making it the most advanced
investigational vaccine against the West Nile virus. Acambis also has the only
vaccine in development against Clostridium difficile bacteria, a leading cause
of hospital-acquired infections. Recognised internationally as the leading
producer of smallpox vaccines, Acambis is developing an investigational smallpox
vaccine, ACAM2000, and is manufacturing emergency-use stockpiles of this
investigational vaccine for the US Government and other governments around the
world. It is also developing an attenuated smallpox vaccine, MVA3000, under
contracts with the US National Institutes of Health.
Acambis is based in Cambridge, UK and Cambridge, Massachusetts, US, and is
listed on the London Stock Exchange (ACM). Its shares are listed on NASDAQ
(ACAM) in the form of American Depositary Receipts. More information is
available at www.acambis.com.
"Safe Harbor" statement under the Private Securities Litigation Reform Act of
1995:
The statements in this news release that are not historical facts are
forward-looking statements that involve risks and uncertainties, including the
timing and results of clinical trials, product development, manufacturing and
commercialisation risks, the risks of satisfying the regulatory approval process
in a timely manner, the need for and the availability of additional capital. For
a discussion of these and other risks and uncertainties see "Risk management" in
the Company's 2005 Annual Report and "Risk factors" in its Form 20-F, in
addition to those detailed on the Company's website and in the Company's filings
made with the Securities and Exchange Commission from time to time. These
forward-looking statements are based on estimates and assumptions made by the
management of Acambis and are believed to be reasonable, though are inherently
uncertain and difficult to predict. Actual results or experience could differ
materially from the forward-looking statements.
Enclosure No. 5
SCHEDULE 10
NOTIFICATION OF MAJOR INTERESTS IN SHARES
1. Name of company
Acambis plc
2. Name of shareholder having a major interest
Legal & General Investment Management Limited
3. Please state whether notification indicates that it is in respect of holding
of the shareholder named in 2 above or in respect of a non-beneficial interest
or in the case of an individual holder if it is a holding of that person's
spouse or children under the age of 18
As above
4. Name of the registered holder(s) and, if more than one holder, the number of
shares held by each of them
HSBC Bank PLC - various accounts
5. Number of shares / amount of stock acquired
N/A
6. Percentage of issued class
N/A
7. Number of shares / amount of stock disposed
Not disclosed
8. Percentage of issued class
Not disclosed
9. Class of security
Ordinary shares of 10p each
10. Date of transaction
Not disclosed
11. Date company informed
23 November 2006
12. Total holding following this notification
6,404,239 shares
13. Total percentage holding of issued class following this notification
5.96%
14. Any additional information
N/a
15. Name of contact and telephone number for queries
Elizabeth Brown, Company Secretary
+44 (0) 1223 275 300
16. Name and signature of authorised company official responsible for making
this notification
Elizabeth Brown
Date of notification
24 November 2006
The FSA does not give any express or implied warranty as to the accuracy of this
document or material and does not accept any liability for error or omission.
The FSA is not liable for any damages (including, without limitation, damages
for loss of business or loss of profits) arising in contract, tort or otherwise
from the use of or inability to use this document, or any material contained in
it, or from any action or decision taken as a result of using this document or
any such material.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant Peptide Therapeutics Group has duly caused this report to be
signed on its behalf by the undersigned, thereunto duly authorized.
Date: 30 November, 2006 ACAMBIS PLC
By: /s/ Lyndsay Wright
Name: Lyndsay Wright
Title: VP, Communications and IR.